Aardvark Therapeutics Faces Securities Fraud Lawsuit
Investors who lost money in Aardvark Therapeutics, Inc. (AARD) are being given the opportunity to lead a securities fraud class action lawsuit. The suit alleges misleading statements about the company's business and the safety of its ARD-101 drug.
Company: Los Angeles, October 9, 2026 – The Law Offices of Howard G. Smith has announced an opportunity for investors with substantial losses in Aardvark Therapeutics, Inc. (AARD) to lead a securities fraud class action lawsuit against the company.
The Lawsuit Allegations: The complaint alleges that between February 10, 2025, and May 14, 2026, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business operations and prospects. Specifically, the lawsuit claims that the company misrepresented the safety of its product candidate ARD-101, thereby overstating its clinical, regulatory, and commercial potential.
Call for Lead Plaintiff: Investors who incurred losses in Aardvark Therapeutics and wish to participate in the lawsuit are encouraged to contact The Law Offices of Howard G. Smith by October 31, 2026. The firm is available to discuss legal rights via email, phone, or their website.
Summary: The class action lawsuit centers on allegations that Aardvark Therapeutics misled investors regarding its drug development and product safety. Investors who experienced financial losses due to these alleged misrepresentations have the opportunity to come forward and potentially lead the legal action.